DOCSLIB.ORG

Open Bas Dissertation 010716.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Open Bas Dissertation 010716.Pdf The Pennsylvania State University The Graduate School College of Agricultural Sciences A STUDY ON THE EFFECT OF DELIVERY VEHICLES ON THE EFFICACY OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS BB-12 IN HUMANS A Dissertation in Food Science by Zhaoyong Ba © 2016 Zhaoyong Ba Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy May 2016 The dissertation of Zhaoyong Ba was reviewed and approved* by the following: Robert F. Roberts Department Head of Food Science Professor of Food Science Dissertation Advisor Chair of Committee Ryan J. Elias Frederik Sr. and Faith E. Rasmussen Professor of Food Science Associate Professor of Food Science Rodolphe Barrangou Adjunct Professor of Food Science Associate Professor of Food, Bioprocessing and Nutrition Sciences North Carolina State University Penny M. Kris-Etherton Distinguished Professor of Nutrition James L. Rosenberger Director of SCC and Online Programs Professor of Statistics *Signatures are on file in the Graduate School Abstract Bifidobacterium animalis subsp. lactis BB-12 (BB-12) is a probiotic strain that has been used as a food ingredient and food supplement worldwide since 1985 with well- documented health benefits. It has been commonly delivered in fermented dairy products for perceived health benefits including facilitating bowel transit, increasing gut short chain fatty acid (SCFA) production, and modifying gut microbiota (increase the ratio of potentially beneficial to harmful microbes). In addition to traditional fermented dairy- based probiotic-containing products, many new types of probiotic-containing products such as juice-based, chocolate-based, and capsules have been developed. While these provide more options for people to access probiotics, little research has been done on the effect of delivery matrix (dairy vs. non-dairy) on the efficacy of BB-12 in humans. In addition, it was not clear how yogurt fermentation might impact the survival of BB-12 in the product or on its performance in vivo. In order to address these questions, a randomized clinical trial was conducted using BB-12 delivered by capsule (CAP) or yogurt smoothies. The first step in the project was to identify a selective medium for the enumeration of BB-12 in yogurt product where high concentration of live cultures Lactobacillus delbrueckii subsp. bulgaricus (LB) and Streptococcus thermophilus (ST) are present. After evaluation of different selective media, the MRS-NNLP agar was found to effectively inhibit growth of ST and LB, and was subsequently chosen for BB-12 enumeration. Then three yogurt smoothies: 1) a control yogurt smoothie without BB-12 (YS), 2) a yogurt smoothie with BB-12 added pre-fermentation (PRE), or 3) post- iii fermentation (POST), were developed. Compositions (fat and total solids) of the yogurt smoothies were measured following each production. The concentration of BB-12, ST, LB, and pH of the products were measured weekly during shelf life. Data from 27 batches indicated the BB-12 population in the yogurt smoothies was stable during shelf life and comparable within and across batches. The population of BB-12 declined in both PRE and POST throughout shelf life and was found to decrease faster in the POST drink as compared to the PRE drink. The BB-12 remained at the specified dose level (log10 10 ± 0.5 CFU per/serving) throughout shelf life of the products. The second objective was to evaluate the effect of BB-12 interventions on the gut transit time and fecal SCFA production in healthy adults. A total of 36 healthy adults aged 18-40 years with a BMI of 20-35 kg/m2 were recruited in this controlled, 4-period crossover, free-living study. Participants received each of the 4 treatments in a random order. When consuming yogurt smoothies, participants consumed 240 g of yogurt smoothie per day or on the capsule treatment, they consumed a probiotic capsule per day, receiving a dose of log 10 ± 0.5 CFU of BB-12/day. Dietary intake of total calories and various nutrients were assessed via self-reported 3-day dietary recall. Gut transit times were measured at baseline using the blue dye and a telemetry device known as a SmartPill®, and after each treatment using SmartPill® only. Stool and blood samples were collected at baseline and after each treatment. Fecal SCFAs were extracted using ethyl acetate and analyzed by gas chromatography (GC). A significant positive correlation (Spearman rho = 0.67, P < 0.0001) was observed between blue dye and SmartPill® transit times, suggesting that the blue dye method remained a reliable cost-efficient approach for iv baseline screening for whole gut transit time (WGTT). No significant treatment effect was observed on either GTT or fecal SCFAs. However, this study is the first to demonstrate the possible relationships among regional gut transit times and fecal SCFAs in healthy adults, and the results from this study confirmed a number of correlations that have been reported previously. Notably, the predominant SCFAs negatively correlated with WGTT, colonic transit time (CTT), and gastric emptying time (GET), but had little to do with small bowel transit time (SBTT). The third objective was to survey the gut microbiota of participants before and after different BB-12 interventions. Bacterial genomic DNA was isolated from fecal samples using the MOBIO PowerSoil DNA isolation kit according to the manufacturer’s protocol with modifications. The DNA samples were amplified for the V4 region of the 16S rRNA gene. Amplicons were then sequenced at the DNA Technologies Core Facility of the University of California, Davis on an Illumina® Genome Analyzer II sequencing platform. After removing samples with low quality and poor compliances, about 2.4 million sequences from 147 stool samples were analyzed using QIIME. Overall, 10 phyla and 109 genera were identified in the participants. Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria accounted for > 98% of the sequences at the phylum level. No significant treatment effect on the gut microbiota was detected due to the large interpersonal and intrapersonal variations observed except that yogurt interventions resulted in a higher relative abundance of Streptococcus than the capsule treatment. A significant gender effect was observed when comparing the gut microbiota of the present study cohort. v In an effort to understand the relationships between gut microbiota and host immune and metabolic responses, the beta-diversity results were grouped by parameters including sex, body mass index (BMI), blood pressure, glucose, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TGs), tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), and etc., a number of statistically significant differences were found. However, further studies are needed to validate these relationships, because either only a small percentage of difference could be explained by the grouping, or only a few data points were in one of the two arms. To further explore the effect of the interventions on the relative abundance of members of Bifidobacterium genus, DNA samples were analyzed using bifidobacteria specific terminal restriction fragment length polymorphism (Bif-TRFLP). Interestingly, the two BB-12-containing yogurt smoothies (PRE and POST) resulted in significantly higher percentage of B. animalis when compared to baseline, to the BB-12-free yogurt smoothie (YS), to the BB-12 containing capsule (CAP), and after final washout. In conclusion, the BB-12 survived well in yogurt smoothies throughout shelf life (< 1 log decrease) and survived better in the pre-added treatment than in the post-added product perhaps due to BB-12’s adaptation to the acidic environment during fermentation. Little treatment effect was observed on either GTT or fecal SCFAs. The predominant SCFAs negatively correlated with regional transit times except for SBTT. Small treatment effect on the gut microbiota was detected while gender effect was found to be significant in the present study cohort. BB-12 containing yogurt smoothies resulted in higher relative abundance of B. animalis than BB-12 containing capsule. vi Table of Contents List of Figures ................................................................................................................... xi List of Tables .................................................................................................................. xiii List of Abbreviations ..................................................................................................... xiv Acknowledgements ........................................................................................................ xix Chapter 1 - Literature Review ......................................................................................... 1 1.1. Probiotics ................................................................................................................. 1 1.2. The Genus Bifidobacterium ................................................................................... 2 1.3. Bifdobacteriam animalis subsp. lactis .................................................................... 4 1.4. Bifidobacterium animalis ssp. lactis BB-12 ........................................................... 5 1.5. Probiotic Effects of BB-12 ..................................................................................... 6 1.5.1. BB-12 and GI Health ......................................................................................... 7 1.5.2. BB-12 and Immune Health .............................................................................
Load more

Recommended publications
  • Bifidobacterium Response to Lactulose Ingestion in the Gut Relies on A
    ARTICLE https://doi.org/10.1038/s42003-021-02072-7 OPEN Bifidobacterium response to lactulose ingestion in the gut relies on a solute-binding protein- dependent ABC transporter ✉ Keisuke Yoshida 1 , Rika Hirano2,3, Yohei Sakai4, Moonhak Choi5, Mikiyasu Sakanaka 5,6, Shin Kurihara3,6, Hisakazu Iino7, Jin-zhong Xiao 1, Takane Katayama5,6 & Toshitaka Odamaki1 This study aims to understand the mechanistic basis underlying the response of Bifido- bacterium to lactulose ingestion in guts of healthy Japanese subjects, with specific focus on a lactulose transporter. An in vitro assay using mutant strains of Bifidobacterium longum subsp. 1234567890():,; longum 105-A shows that a solute-binding protein with locus tag number BL105A_0502 (termed LT-SBP) is primarily involved in lactulose uptake. By quantifying faecal abundance of LT-SBP orthologues, which is defined by phylogenetic analysis, we find that subjects with 107 to 109 copies of the genes per gram of faeces before lactulose ingestion show a marked increase in Bifidobacterium after ingestion, suggesting the presence of thresholds between responders and non-responders to lactulose. These results help predict the prebiotics- responder and non-responder status and provide an insight into clinical interventions that test the efficacy of prebiotics. 1 Next Generation Science Institute, RD Division, Morinaga Milk Industry Co., Ltd., Zama, Japan. 2 Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Nonoichi, Japan. 3 Biology-Oriented Science and Technology, Kindai University, Kinokawa, Japan. 4 Food Ingredients and Technology Institute, RD Division, Morinaga Milk Industry Co., Ltd, Zama, Japan. 5 Graduate School of Biostudies, Kyoto University, Kyoto, Japan. 6 Faculty of Bioresources and Environmental Sciences, Ishikawa Prefectural University, Nonoichi, Japan.
    [Show full text]
  • Recursos Naturales - Referencias Bibliográficas
    Recursos Naturales - Referencias Bibliográficas Nombre Nombre # Referencia Común Científico Afsar Shaik; Rupesh S Kanhere; Rajaram Cuddapah; Nelson Kumar S; Artemisa, Artemisia Prasanth Reddy Vara; Saisaran Sibyala. Antifertility activity of Artemisia 1 Mugwort vulgaris L. vulgaris leaves on female Wistar rats. Chinese Journal of Natural Medicines 2014, 12(3): 0180-0185 Diandra Araújo Luz, Alana Miranda Pinheiro; Mallone Lopes Silva; Marta Chagas Monteiro; Rui Daniel Prediger; Cristiane Socorro Ferraz Maia; Petiveria 2 Anamú Enéas Andrade Fontes-Júnior. Ethnobotany, phytochemistry and alliacea L. neuropharmacological effects of Petiveria alliacea L. (Phytolaccaceae): A review. Journal of Ethnopharmacology 185 (2016) 182–201 Plantago B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 4° 3 Llantén major L. Edición. p334-335 Turnera B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 3° 4 Damiana diffusa Wild. Edición. p178-179. var. Aesculus Castaño de B. Vanaclocha; S. Cañigueral. Fitoterapia Vademécum de Prescripción. 3° 5 hippocastanu Indias Edición. p172-175 m 1.- Chung-Hua Hsu & Col. The Mushroom Agaricus blazei Murill Extract Normalizes Liver Function in Patients with Chronic Hepatitis B. The Journal of Alternative and Complementary Medicine. Volume 14, Number 3, 2008, pp. 299–301 2.- Diogo G. Valadares, Mariana C. Duarte, Laura Ramírez, Miguel A. Chávez-Fumagalli, Eduardo A.F. Coelho. Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis. Experimental Parasitology, Volume 132, Issue 2, October 2012, Pages 228-236 6 Setas Agaricus blazei 3.- Chung-Hua Hsu & Col. The Mushroom Agaricus blazei Murill in Combination with Metformin and Gliclazide Improves Insulin Resistance in Type 2 Diabetes: A Randomized, Double-Blinded, and Placebo- Controlled Clinical Trial.
    [Show full text]
  • Delivery of Metabolically Neuroactive Probiotics to the Human Gut
    International Journal of Molecular Sciences Article Delivery of Metabolically Neuroactive Probiotics to the Human Gut Peter A. Bron 1, Marta Catalayud 2 , Massimo Marzorati 2,3, Marco Pane 3, Ece Kartal 4 , Raja Dhir 1 and Gregor Reid 5,6,* 1 Seed Health, 2100 Abbot Kinney Blvd Suite G Venice, Los Angeles, CA 90291, USA; [email protected] (P.A.B.); [email protected] (R.D.) 2 ProDigest BV, Technologiepark-Zwijnaarde 94, 9052 Gent, Belgium; [email protected] (M.C.); [email protected] (M.M.) 3 Probioticial, Via Enrico Mattei 3, 28100 Novara, Italy; [email protected] 4 Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Heidelberg University, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany; [email protected] 5 Centre for Human Microbiome and Probiotic Research, Lawson Health Research Institute, 268 Grosvenor Street, London, ON N6A 4V2, Canada 6 Departments of Microbiology and Immunology, and Surgery, Western University, London, ON N6A 3K7, Canada * Correspondence: [email protected] Abstract: The human microbiome is a rich factory for metabolite production and emerging data has led to the concept that orally administered microbial strains can synthesize metabolites with neuroactive potential. Recent research from ex vivo and murine models suggests translational potential for microbes to regulate anxiety and depression through the gut-brain axis. However, so far, less emphasis has been placed on the selection of specific microbial strains known to produce the required key metabolites and the formulation in which microbial compositions are delivered to the Citation: Bron, P.A.; Catalayud, M.; gut. Here, we describe a double-capsule technology to deliver high numbers of metabolically active Marzorati, M.; Pane, M.; Kartal, E.; Dhir, R.; Reid, G.
    [Show full text]
  • Our Probiotic Strains Str Ou Ainsr Or Pr S Tobioic
    THERAPEUTIC IndEx GAStroenteroloGy pag. 5 OUROUR PROBIOTICPROOBIOTTIC ImmunoloGy pag. 17 DermAtoloGy pag. 21 STRAINSSTRRAINSS AntI-AGInG pag. 23 CArDIoloGy/ metAbolISm pag. 27 DIetetICS pag. 29 GIneColoGy pag. 31 uroloGy pag. 39 Gut-brAIn pag. 43 Probiotics like nobody else OurOur InnovativeInnovative orAl CAre pag. 47 Probiotical S.p.A. Via E. Mattei, 3, 28100 Novara (NO), Italy - T: +39 0321 46 59 33 61 Strains:Sttrains:i F: +39 0321 49 26 93 - email: [email protected] - www.probiotical.com teChnoloGIeS pag. 49 ReadyReaddy forfor YourYour HealthHeallth tHeraPeUtiC index GastroenteroloGy pag. 5 ImmunoloGy pag. 17 DermatoloGy pag. 20 antI-aGInG pag. 22 CarDIoloGy/metabolIsm pag. 25 DIetetICs pag. 27 GIneColoGy pag. 29 uroloGy pag. 37 Gut-braIn pag. 41 oral Care pag. 44 teChnoloGIes pag. 45 Romane Catalogo Indice 13-5-20:Layout 1 26/05/20 17:44 Pagina 1 Probiotical is driving probiotics innovation since 1985. Our expertise comprises strain selection, advanced R&D, production of strains to finished products with all guarantees of stability and demonstrated efficacy in many functionalities. Our strains can be proposed in allergen-free quality, microencapsulated, and standardized in different concentrations. Strains available as raw material can be provided in bulk or as customized finished products. Strains available as finished dosage form can be provided only as Probiotical finished products. Romane Catalogo Indice 13-5-20:Layout 1 26/05/20 17:44 Pagina 3 StrainS & blendS index Bifidobacterium • Bifidobacterium breve - BR03™ (DSM 16604) Gastroenterology: Strain: pag. 8, 15 - Blend: pag. 5, 6, 8, 10, 14 ; Dermatology: Blend: pag. 21 ; Dietetics: Strain: pag.
    [Show full text]
  • PROBIOTICS, PREBIOTICS NEW FOODS, NUTRACEUTICALS and BOTANICALS for NUTRITION & HUMAN and MICROBIOTA HEALTH SCIENTIFIC ORGANISERS L
    rome - september 10/12, 2017 università urbaniana PROBIOTICS, PREBIOTICS NEW FOODS, NUTRACEUTICALS AND BOTANICALS for NUTRITION & HUMAN and MICROBIOTA HEALTH SCIENTIFIC ORGANISERS L. Capurso (Italy) A. Gasbarrini (Italy) A. Guarino (Italy) L. Morelli (Italy) INTERNATIONAL SCIENTIFIC COMMITTEE G. Barbara (Italy) R. Berni CananiPROBIOTICS, (Italy) PREBIOTICS P. Brigidi (Italy) M. L. Colombo NEW (Italy) FOODS, NUTRACEUTICALS AND BOTANICALS G. Delle Favefor NUTRITION(Italy) & HUMAN and MICROBIOTA HEALTH J. Dorè (France) V. Fogliano (The Netherlands) F. Guarner (Spain) M. Rescigno (Italy) H. Tilg (Austria) K. M. Tuohy (Italy) PEDIATRIC DAY A. Guarino (Italy) SCIENTIFIC REFEREES M. Anti (Italy) G. Capurso (Italy) M. Koch (Italy) UNDER THE PATRONAGE OF UNDER THE PATRONAGE OF Associazione Giovani Gastroenterologi ed Endoscopisti Italiani SIGE, Società Italiana di Gastroenterologia European Association for Gastroenterology, Endoscopy & Nutrition 5/7/2017 logo.JPG MTCC, Mediterranean Task Force for Cancer Control https://mail.google.com/mail/u/0/#inbox?projector=1 1/1 index Sunday, September 10 Aula Magna p. 8 Aula Élie Metchnikoff p. 11 Monday, September 11 Aula Magna p. 15 Aula Élie Metchnikoff p. 18 Tuesday, September 12 Aula Magna p. 20 Aula Élie Metchnikoff p. 22 Proceedings p. 27 Oral Communications p. 75 Posters p. 89 Faculty p. 126 Index of Authors p. 130 SCIENTIFIC PROGRAMME Abstract Authors Countries p. 133 General Information p. 134 Scientific Information p. 139 Exhibition Area p. 142 aula magna sunday, SEPTEMBER 10 sunday, SEPTEMBER 10 AULA magna 08.30-10.00 a.m. YOUNG ITALIAN GASTROENTEROLOGISTS (AGGEI) 02.00-03.00 p.m. OPENING CEREMONY MEET THE EXPERT: QUESTIONS AND ANSWERS Chairs: L.
    [Show full text]
  • Cosmeceutical Importance of Fermented Plant Extracts: a Short Review
    International Journal of Applied Pharmaceutics ISSN- 0975-7058 Vol 10, Issue 4, 2018 Review Article COSMECEUTICAL IMPORTANCE OF FERMENTED PLANT EXTRACTS: A SHORT REVIEW BHAGAVATHI SUNDARAM SIVAMARUTHI, CHAIYAVAT CHAIYASUT, PERIYANAINA KESIKA * Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand Email: [email protected] Received: 30 Mar 2018, Revised and Accepted: 24 May 2018 ABSTRACT Personal care products, especially cosmetics, are regularly used all over the world. The used cosmetics are discharged continuously into the environment that affects the ecosystem and human well-being. The chemical and synthetic active compounds in the cosmetics cause some severe allergies and unwanted side effects to the customers. Currently, many customers are aware of the product composition, and they are stringent in product selection. So, cosmetic producers are keen to search for an alternative, and natural active principles for the development and improvisation of the cosmetic products to attain many customers. Phytochemicals are known for several pharmacological and cosmeceutical applications. Fermentation process improved the quality of the active phytochemicals and also facilitates the easy absorption of them by human system. Recently, several research groups are working on the cosmeceutical importance of fermented plant extracts (FPE), particularly on anti-ageing, anti-wrinkle, and whitening property of FPE. The current manuscript is presenting a brief
    [Show full text]
  • WO 2018/064165 A2 (.Pdf)
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/064165 A2 05 April 2018 (05.04.2018) W !P O PCT (51) International Patent Classification: Published: A61K 35/74 (20 15.0 1) C12N 1/21 (2006 .01) — without international search report and to be republished (21) International Application Number: upon receipt of that report (Rule 48.2(g)) PCT/US2017/053717 — with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 27 September 2017 (27.09.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/400,372 27 September 2016 (27.09.2016) US 62/508,885 19 May 2017 (19.05.2017) US 62/557,566 12 September 2017 (12.09.2017) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSI¬ TY OF TEXAS SYSTEM [US/US]; 210 West 7th St., Austin, TX 78701 (US). (72) Inventors: WARGO, Jennifer; 1814 Bissonnet St., Hous ton, TX 77005 (US). GOPALAKRISHNAN, Vanch- eswaran; 7900 Cambridge, Apt. 10-lb, Houston, TX 77054 (US). (74) Agent: BYRD, Marshall, P.; Parker Highlander PLLC, 1120 S. Capital Of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • GRAS Notice 855, Bifidobacterium Animalis Subsp. Lactis Strain R0421
    GRAS Notice (GRN) No. 855 https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory JHeimbach LLC April 3, 2019 Paulette Gaynor, Ph.D. Senior Regulatory Project Manager Division of Biotechnology and GRAS Notice Review (HFS-255) Office of Food Additive Safety Center for Food Safety and Applied Nutrition Food and Drug Administration 5100 Paint Branch Parkway College Park, MD 20740 Dear Dr. Gaynor: Pursuant to 21 CFR Part 170, Subpart E, Lallemand Health Solutions (Lallemand), through me as its agent, hereby provides notice of a claim that the addition to non-exempt milk-based term infant formula of Bifidobacteriurn anirnalis ssp. lactis strain R0421 is exempt from the premarket approval requirement of the Federal Food, Drug, and Cosmetic Act because Lallemand has determined that the intended use is generally recognized as safe (GRAS) based on scientific procedures. As required, one copy of the GRAS monograph and one signed copy of the statement of the Expert Panel are provided. Additionally, I have enclosed a virus-free CD-ROM with the GRAS monograph and the signed statement of the Expert Panel. If you have any questions regarding this notification, please feel free to contact me at 804-742-5543 o~ jheimbach.com. Si11~1/ ""James t. Heimbach, Ph.D., F.A.C.N. President Encl. ~~~~u~~lg) APR 8 2019 OFFICE OF 923 Water Street, P.O. Box 66, Port Royal Virginia 22535, USA FOOD ADDITl\/1: SAFETY tel. (+1) 804-742-5543 fax (+1) 202-478-0986 [email protected] LALLEMAND HEALTH SOLUTIONS Generally Recognized as Safe (GRAS) Determination for the Use of Bifidobacterium animalis subsp.
    [Show full text]
  • Targeting the Gut Microbiome in Allogeneic Hematopoietic Stem Cell Transplantation
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058198; this version posted June 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Targeting the gut microbiome in allogeneic hematopoietic stem cell transplantation Marcel A. de Leeuw & Manuel X. Duval, GeneCreek List of Figures Contents 1 GM composition evolution across allo-HSCT . 2 I 2 Baseline GM composition and conditioning level . 3 NTRODUCTION 1 3 Top 10 variable importances estimated by the ran- dom survival forest models .............. 3 MATERIALS & METHODS 2 4 Biological safety level and aGvHD at onset . 3 DATA ANALYSIS .................. 2 5 Relative importance of regressors explaining the RESULTS 2 aGvHD status ...................... 3 OVERALL GM COMPOSITION EVOLUTION ACROSS 6 Co-exclusion by and co-occurrence with QPS species 4 ALLO-HSCT ................. 2 List of Tables CORRELATION BETWEEN CONDITIONING AND THE GM 2 BASELINE GM COMPOSITION AND SURVIVAL . 3 1 Prospective data sets used in the study . 1 AGVHD CASES, CONTROLS AND GM COMPOSITION 3 IMMUNO-MODULATING METABOLITES . 4 IN SILICO SCREENING OF THE ALLO-HSCT GM . 4 DISCUSSION 4 CONCLUSIONS 6 SUMMARY 6 DECLARATIONS 6 BIBLIOGRAPHY 7 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Revised manuscript medRxiv preprint doi: https://doi.org/10.1101/2020.04.08.20058198; this version posted June 9, 2020.
    [Show full text]
  • Tolerance and Safety of Lactobacillus Paracasei Ssp. Paracasei in Combination with Bifidobacterium Animalis Ssp
    Downloaded from British Journal of Nutrition (2009), 102, 869–875 doi:10.1017/S0007114509289069 q The Authors 2009 https://www.cambridge.org/core Tolerance and safety of Lactobacillus paracasei ssp. paracasei in combination with Bifidobacterium animalis ssp. lactis in a prebiotic-containing infant formula: a randomised controlled trial . IP address: Arine M. Vlieger1*, Afke Robroch1, Stef van Buuren2,3, Jeroen Kiers4,5, Ger Rijkers6, 7 4 Marc A. Benninga and Rob te Biesebeke 170.106.202.8 1Department of Paediatrics, St Antonius Hospital, Nieuwegein, The Netherlands 2Department of Statistics, TNO Quality of Life, Leiden, The Netherlands 3 Department of Methodology and Statistics, FSS, University of Utrecht, The Netherlands , on 4 Global Development Centre, Friesland Foods, Leeuwarden, The Netherlands 26 Sep 2021 at 01:49:26 5NIZO, Ede, The Netherlands 6Department of Microbiology and Immunology, St Antonius Hospital, Nieuwegein, The Netherlands 7Department of Paediatric Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands (Received 11 September 2008 – Revised 29 January 2009 – Accepted 3 February 2009 – First published online 31 March 2009) , subject to the Cambridge Core terms of use, available at The addition of probiotics to infant formula has been shown to be an efficient way to increase the number of beneficial bacteria in the intestine in order to promote a gut flora resembling that of breast-fed infants. The objective of the present study was to evaluate the safety and tolerance of a combination of two probiotic strains in early infancy. A group of 126 newborns were randomised to receive a prebiotic-containing starter formula supplemented with Lactobacillus paracasei ssp. paracasei and Bifidobacterium animalis ssp.
    [Show full text]
  • The Pennsylvania State University the Graduate School Department
    The Pennsylvania State University The Graduate School Department of Food Science EFFECT OF STARCH SPHERULITES ON SURVIVAL OF BIFIDOBACTERIA IN THE PRESENCE OF ACID OR BILE A Thesis in Food Science by Srilatha Chittiprolu 2009 Srilatha Chittiprolu Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science May 2009 ii The thesis of Srilatha Chittiprolu was reviewed and approved* by the following: Robert F. Roberts Associate Professor of Food Science Thesis Advisor Stephen J. Knabel Professor of Food Science Gregory R. Ziegler Professor of Food Science John D. Floros Professor of Food Science Head of the Department of Food Science *Signatures are on file in the Graduate School iii ABSTRACT Probiotics are live microorganisms which have been shown to confer a health benefit on the host, when administered in sufficient amounts (FAO/WHO, 2001). Many of the probiotic bacteria currently used in foods and dietary supplements are members of Lactic Acid Bacteria. Strains of the genus Bifidobacterium are widely used as probiotics for human consumption. Bifidobacteria are often sensitive to stresses encountered during production and storage of food and during passage through the gastrointestinal tract. Thus, the overall purpose of this research was to determine if adhesion of bifidobacteria to starch-based spherulites can improve their survival when exposed to acid or bile. The first objective of this work was to develop a procedure to prepare spherulites in adequate quantities for use in adhesion and survival studies. Spherulites were prepared successfully in a Parr reactor (pressure vessel) using potato starch, high amylose maize starch (Hylon VII) and purified potato amylose.
    [Show full text]
  • Insight Into Alternative Approaches for Control of Avian Influenza in Poultry, with Emphasis on Highly Pathogenic H5N1
    Viruses 2012, 4, 3179-3208; doi:10.3390/v4113179 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Insight into Alternative Approaches for Control of Avian Influenza in Poultry, with Emphasis on Highly Pathogenic H5N1 E. M. Abdelwhab †,* and Hafez M. Hafez Institute of Poultry Diseases, Free Berlin University, Königsweg 63, 14163 Berlin, Germany; E-Mail: [email protected] † Present address: Molecular Pathogenesis and Ecology of Influenza Viruses Laboratory, Institute of Molecular Biology, Federal Research Institute for Animal Health, Friedrich Loeffler Institute, Isles of Riems, Suedufer 10, 17493 Greifswald, Germany * Author to whom correspondence should be addressed; E-Mails: [email protected]; [email protected]; Tel.: +49-30-8386-2679; +49-38-3517-1263; +49-38-3517-1237; Fax: +49-30-838-6267; +49-38-3517-1275. Received: 23 September 2012; in revised form: 4 November 2012 / Accepted: 8 November 2012 / Published: 19 November 2012 Abstract: Highly pathogenic avian influenza virus (HPAIV) of subtype H5N1 causes a devastating disease in poultry but when it accidentally infects humans it can cause death. Therefore, decrease the incidence of H5N1 in humans needs to focus on prevention and control of poultry infections. Conventional control strategies in poultry based on surveillance, stamping out, movement restriction and enforcement of biosecurity measures did not prevent the virus spreading, particularly in developing countries. Several challenges limit efficiency of the vaccines to prevent outbreaks of HPAIV H5N1 in endemic countries. Alternative and complementary approaches to reduce the current burden of H5N1 epidemics in poultry should be encouraged. The use of antiviral chemotherapy and natural compounds, avian-cytokines, RNA interference, genetic breeding and/or development of transgenic poultry warrant further evaluation as integrated intervention strategies for control of HPAIV H5N1 in poultry.
    [Show full text]